tetano
Editor, Senior Moderator
Cytokine Growth Factor Rev
. 2022 Jan 8;S1359-6101(22)00002-8.
doi: 10.1016/j.cytogfr.2022.01.002. Online ahead of print.
Before the "cytokine storm": Boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications
Somit Dutta[SUP] 1 [/SUP], Amartya Mukherjee[SUP] 2 [/SUP], Upendra Nongthomba[SUP] 3 [/SUP]
Affiliations
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic, and causes many health complications, including major lung diseases. Besides investigations into the virology of SARS-CoV-2, understanding the immunological routes underlying the clinical manifestations of COVID-19 is important for developing effective therapeutic interventions. The clearance of SARS-CoV-2-infected apoptotic cells by professional efferocytes, through a process termed as 'efferocytosis', is essential for maintaining tissue homeostasis, and reducing the chances of health complications caused by SARS-CoV-2 infection. In this review, we focus on the cellular events leading to engagement of the SARS-CoV-2 with type 2 alveolar cells, and how SARS-COV-2 infection impairs the macrophage anti-inflammatory programming. We also discuss accounts of impaired efferocytosis, and the "cytokine storm" which occur concomitantly with the SARS-CoV-2 infection. Finally, we propose how targeting impaired efferocytosis, due to the SARS-CoV-2 infection, may be a beneficial therapeutic strategy to combat COVID-19, and its complications.
Keywords: ARDS; Apoptosis; Autoimmune disease; COVID-19; Cytokine storm; Diabetes; Efferocytosis; Inflammation; Phagocytosis; SARS-CoV-2.
. 2022 Jan 8;S1359-6101(22)00002-8.
doi: 10.1016/j.cytogfr.2022.01.002. Online ahead of print.
Before the "cytokine storm": Boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications
Somit Dutta[SUP] 1 [/SUP], Amartya Mukherjee[SUP] 2 [/SUP], Upendra Nongthomba[SUP] 3 [/SUP]
Affiliations
- PMID: 35039221
- DOI: 10.1016/j.cytogfr.2022.01.002
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic, and causes many health complications, including major lung diseases. Besides investigations into the virology of SARS-CoV-2, understanding the immunological routes underlying the clinical manifestations of COVID-19 is important for developing effective therapeutic interventions. The clearance of SARS-CoV-2-infected apoptotic cells by professional efferocytes, through a process termed as 'efferocytosis', is essential for maintaining tissue homeostasis, and reducing the chances of health complications caused by SARS-CoV-2 infection. In this review, we focus on the cellular events leading to engagement of the SARS-CoV-2 with type 2 alveolar cells, and how SARS-COV-2 infection impairs the macrophage anti-inflammatory programming. We also discuss accounts of impaired efferocytosis, and the "cytokine storm" which occur concomitantly with the SARS-CoV-2 infection. Finally, we propose how targeting impaired efferocytosis, due to the SARS-CoV-2 infection, may be a beneficial therapeutic strategy to combat COVID-19, and its complications.
Keywords: ARDS; Apoptosis; Autoimmune disease; COVID-19; Cytokine storm; Diabetes; Efferocytosis; Inflammation; Phagocytosis; SARS-CoV-2.